$7.87
+3.96%Oct 19, 2026, 12:00 UTC
DiaMedica Therapeutics rescheduled its virtual fetal growth restriction key opinion leader webinar to November 24, 2026, at 8:00 a.m. Eastern Time.
Source:Sep 30, 2026, 12:30 UTC
DiaMedica Therapeutics announced it will host a virtual key opinion leader webinar on October 23, 2026 to discuss DM199 (rinvecalinase alfa) for fetal growth restriction, including early Phase 2 FGR results.
Source:Aug 11, 2026, 13:05 UTC
DiaMedica Therapeutics reported its second-quarter progress and financial results, highlighting advancement of DM199 in early-onset fetal growth restriction, preeclampsia, and acute ischemic stroke, and a cash runway expected to extend through 2027.
Jun 23, 2026, 13:00 UTC
DiaMedica Therapeutics dosed the first patients in a Phase 2 trial of DM199 for treating fetal growth restriction.
Source: